About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Medical Oncology and Hematology
›
top-articles
Department of Medical Oncology and Hematology
197
(top 1%)
papers
8.5K
(top 1%)
citations
44
(top 1%)
h
-index
89
(top 1%)
g
-index
206
all documents
8.9K
doc citations
2.0K
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy
Journal of Clinical Oncology
2000
511
2
Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells
Nature
2011
421
3
Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop
Journal of Clinical Oncology
2004
400
4
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
Leukemia
2009
350
5
Targeting the protein kinase C family: are we there yet?
Nature Reviews Cancer
2007
343
6
Novel patterns of response under immunotherapy
Annals of Oncology
2019
343
7
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
Leukemia
2008
341
8
The EGFRvIII variant in glioblastoma multiforme
Journal of Clinical Neuroscience
2009
325
9
Male breast carcinoma
1999
282
10
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
Journal of the National Cancer Institute
2007
279
11
Pooled Analysis of the Prognostic and Predictive Effects of
KRAS
Mutation Status and
KRAS
Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
Journal of Clinical Oncology
2013
270
12
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
Cancer
2010
240
13
K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review
Clinical Lung Cancer
2006
212
14
Molecular predictive and prognostic markers in non-small-cell lung cancer
Lancet Oncology, The
2009
194
15
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Annals of Oncology
2008
165
16
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
Annals of Oncology
2009
147
17
Epoetin Alfa Therapy Increases Hemoglobin Levels and Improves Quality of Life in Patients With Cancer-Related Anemia Who Are Not Receiving Chemotherapy and Patients With Anemia Who Are Receiving Chemotherapy
Journal of Clinical Oncology
2001
143
18
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer
Cancer
2010
143
19
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
Annals of Oncology
2007
139
20
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Blood
2020
127
21
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
Annals of Oncology
2012
125
22
Conventional cancer therapy: promise broken or promise delayed?
Lancet, The
1998
117
23
HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPY
Journal of Urology
1998
106
24
Lung cancer screening using low-dose computed tomography in at-risk individuals: The Toronto experience
Lung Cancer
2010
106
25
The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
Blood
2015
104
26
Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
Journal of Clinical Oncology
2008
100
27
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma
Cancer Chemotherapy and Pharmacology
2011
97
28
Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
Leukemia
2009
81
29
Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology Setting
American Journal of Clinical Oncology: Cancer Clinical Trials
2012
77
30
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
Annals of Oncology
2016
77
31
Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
Urology
2010
75
32
Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome
Journal of Thoracic Oncology
2011
70
33
Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review
Journal of Clinical Oncology
2012
69
34
Delayed emesis: moderately emetogenic chemotherapy
Supportive Care in Cancer
2005
64
35
Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo
European Journal of Cancer
2012
63
36
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma
Cancer
2008
58
37
Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells
Leukemia Research
2010
55
38
Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer
Journal of Thoracic Oncology
2011
55
39
Bereavement Practices of Physicians in Oncology and Palliative Care
Archives of Internal Medicine
2009
51
40
Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon Cancer
Journal of the American College of Surgeons
2009
50
41
A Systematic Review on Drug Interactions in Oncology
Cancer Investigation
2006
49
42
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
British Journal of Cancer
2013
49
43
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma
Cancer
2010
48
44
Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study
European Urology
2014
48
45
Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis
Cancer
2012
47
46
The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life
International Journal of Gynecological Cancer
2021
47
47
Evidence-based recommendations for the use of antiemetics in radiotherapy
Radiotherapy and Oncology
2005
46
48
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).
Urologic Oncology: Seminars and Original Investigations
2014
46
49
D(T)
PACE
as salvage therapy for aggressive or refractory multiple myeloma
British Journal of Haematology
2013
45
50
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines
Supportive Care in Cancer
2005
44
site/software ©
exaly
; All materials licenced under
CC by-SA
.